Literature DB >> 22707231

Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors.

E Venzala1, A L García-García, N Elizalde, P Delagrange, R M Tordera.   

Abstract

RATIONALE: Chronic social defeat stress (CSDS) has been proposed as a model of depression. However, most CSDS studies rely only on the analysis of stress-induced social avoidance. Moreover, the predictive validity of the model has been poorly analyzed, let alone its interaction with biological risk factors.
OBJECTIVES: Here, we explore the validity of CSDS as a depression model. Further, the effect of decreased vesicular glutamate transporter 1 (VGLUT1), as a potential factor enhancing a depressive-like phenotype, was studied.
METHODS: Mice were exposed to CSDS (10 days) followed by saline, venlafaxine, fluoxetine, or tianeptine treatment (30 days). The battery of behaviors included motor activity, memory, anxiety, social interaction, helplessness, and anhedonic-like behavior. Moreover, the behavioral effect of CSDS in VGLUT1 heterozygous (VGLUT1+/-) mice was studied, as well as the regulation of VGLUT1 mRNA.
RESULTS: CSDS induced anhedonia, helplessness, hyperactivity, anxiety, social avoidance, and freezing, as well as downregulation of VGLUT1 mRNA in the amygdala. Repeated venlafaxine showed antidepressant-like activity and both venlafaxine and tianeptine behaved as effective anxiolytics. CSDS-induced social avoidance was reverted by tianeptine. Fluoxetine failed to revert most of the behavioral alterations. VGLUT1+/- mice showed an enhanced vulnerability to stress-induced social avoidance.
CONCLUSION: We suggest that CSDS is not a pure model of depression. Indeed, it addresses relevant aspects of anxiety-related disorders. Firstly, CSDS-induced anhedonia and social avoidance are not associated in this model. Moreover, CSDS might be affecting brain areas mainly involved in the processing of social behavior, such as the amygdala, where the glutamatergic mechanism could play a key role.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22707231     DOI: 10.1007/s00213-012-2754-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  67 in total

1.  The assessment of dependence in the study of stressful life events: validation using a twin design.

Authors:  K S Kendler; L M Karkowski; C A Prescott
Journal:  Psychol Med       Date:  1999-11       Impact factor: 7.723

2.  Emotion recognition patterns in patients with panic disorder.

Authors:  Henrik Kessler; Julia Roth; Joern von Wietersheim; Russell M Deighton; Harald C Traue
Journal:  Depress Anxiety       Date:  2007       Impact factor: 6.505

Review 3.  Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test.

Authors:  Stephanie C Dulawa; Rene Hen
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

4.  A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake.

Authors:  E Onder; U Tural; T Aker
Journal:  Eur Psychiatry       Date:  2005-06-17       Impact factor: 5.361

5.  [Efficacy and tolerability of coaxil (tianeptine) in the therapy of posttraumatic stress disorder].

Authors:  Iu A Aleksandrovskiĭ; A S Avedisova; I V Boev; A O Bukhanovkskiĭ; V M Voloshin; B D Tsygankov; B K Shamreĭ
Journal:  Zh Nevrol Psikhiatr Im S S Korsakova       Date:  2005

6.  Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice.

Authors:  Toshiyuki Kawasaki; Yukio Ago; Koji Yano; Ryota Araki; Yusuke Washida; Hirotaka Onoe; Shigeyuki Chaki; Atsuro Nakazato; Hitoshi Hashimoto; Akemichi Baba; Kazuhiro Takuma; Toshio Matsuda
Journal:  Neuropharmacology       Date:  2010-10-21       Impact factor: 5.250

7.  Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1).

Authors:  R M Tordera; S Totterdell; S M Wojcik; N Brose; N Elizalde; B Lasheras; J Del Rio
Journal:  Eur J Neurosci       Date:  2007-01       Impact factor: 3.386

8.  Altered expression and modulation of activity-regulated cytoskeletal associated protein (Arc) in serotonin transporter knockout rats.

Authors:  Raffaella Molteni; Francesca Calabrese; Paola F Maj; Jocelien D A Olivier; Giorgio Racagni; Bart A Ellenbroek; Marco A Riva
Journal:  Eur Neuropsychopharmacol       Date:  2009-07-03       Impact factor: 4.600

9.  Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum.

Authors:  Silvia Rossi; Valentina De Chiara; Alessandra Musella; Hajime Kusayanagi; Giorgia Mataluni; Giorgio Bernardi; Alessandro Usiello; Diego Centonze
Journal:  J Neurosci       Date:  2008-07-16       Impact factor: 6.167

10.  The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress.

Authors:  Michael Lutter; Ichiro Sakata; Sherri Osborne-Lawrence; Sherry A Rovinsky; Jason G Anderson; Saendy Jung; Shari Birnbaum; Masashi Yanagisawa; Joel K Elmquist; Eric J Nestler; Jeffrey M Zigman
Journal:  Nat Neurosci       Date:  2008-06-15       Impact factor: 24.884

View more
  46 in total

Review 1.  Contribution of Vesicular Glutamate Transporters to Stress Response and Related Psychopathologies: Studies in VGluT3 Knockout Mice.

Authors:  Hanga Réka Horváth; Csilla Lea Fazekas; Diána Balázsfi; Subodh Kumar Jain; József Haller; Dóra Zelena
Journal:  Cell Mol Neurobiol       Date:  2017-08-03       Impact factor: 5.046

2.  Molecular Adaptations to Social Defeat Stress and Induced Depression in Mice.

Authors:  Natalya Bondar; Leonid Bryzgalov; Nikita Ershov; Fedor Gusev; Vasiliy Reshetnikov; Damira Avgustinovich; Mikhail Tenditnik; Evgeny Rogaev; Tatiana Merkulova
Journal:  Mol Neurobiol       Date:  2017-05-12       Impact factor: 5.590

3.  Differences in FKBP51 regulation following chronic social defeat stress correlate with individual stress sensitivity: influence of paroxetine treatment.

Authors:  Klaus V Wagner; Daria Marinescu; Jakob Hartmann; Xiao-Dong Wang; Christiana Labermaier; Sebastian H Scharf; Claudia Liebl; Manfred Uhr; Florian Holsboer; Marianne B Müller; Mathias V Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

Review 4.  Social stress models in depression research: what do they tell us?

Authors:  Francis Chaouloff
Journal:  Cell Tissue Res       Date:  2013-03-27       Impact factor: 5.249

Review 5.  Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders.

Authors:  Marc Fakhoury
Journal:  Mol Neurobiol       Date:  2015-04-01       Impact factor: 5.590

Review 6.  Stress, sex, and motivated behaviors.

Authors:  Abigail Laman-Maharg; Brian C Trainor
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

7.  Key role of the 5-HT1A receptor addressing protein Yif1B in serotonin neurotransmission and SSRI treatment.

Authors:  Vincent Martin; Lionel Mathieu; Jorge Diaz; Haysam Salman; Jeanine Alterio; Caroline Chevarin; Laurence Lanfumey; Michel Hamon; Mark C Austin; Michèle Darmon; Craig A Stockmeier; Justine Masson
Journal:  J Psychiatry Neurosci       Date:  2020-09-01       Impact factor: 6.186

8.  Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress.

Authors:  Gaurav Patki; Naimesh Solanki; Fatin Atrooz; Farida Allam; Samina Salim
Journal:  Brain Res       Date:  2013-10-03       Impact factor: 3.252

Review 9.  Treatment-resistant depression: are animal models of depression fit for purpose?

Authors:  Paul Willner; Catherine Belzung
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

10.  Social defeat disrupts reward learning and potentiates striatal nociceptin/orphanin FQ mRNA in rats.

Authors:  Andre Der-Avakian; Manoranjan S D'Souza; David N Potter; Elena H Chartoff; William A Carlezon; Diego A Pizzagalli; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2017-03-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.